Abstract Antibody–drug conjugates (ADCs) and immune-checkpoint inhibitors (ICIs) are reshaping breast cancer treatment, but the extent to which individual ADCs induce immunogenic cell death (ICD) remains construct specific.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile